BR112018071087A2 - composições e métodos de vacinação contra o vírus da dengue em crianças e adultos jovens - Google Patents
composições e métodos de vacinação contra o vírus da dengue em crianças e adultos jovensInfo
- Publication number
- BR112018071087A2 BR112018071087A2 BR112018071087-3A BR112018071087A BR112018071087A2 BR 112018071087 A2 BR112018071087 A2 BR 112018071087A2 BR 112018071087 A BR112018071087 A BR 112018071087A BR 112018071087 A2 BR112018071087 A2 BR 112018071087A2
- Authority
- BR
- Brazil
- Prior art keywords
- dengue
- virus
- compositions
- den
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
- C12N2770/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24164—Methods of inactivation or attenuation by serial passage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322167P | 2016-04-13 | 2016-04-13 | |
| US62/322,167 | 2016-04-13 | ||
| PCT/IB2017/052160 WO2017179017A1 (en) | 2016-04-13 | 2017-04-13 | Compositions and methods of vaccination against dengue virus in children and young adults |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018071087A2 true BR112018071087A2 (pt) | 2019-02-26 |
Family
ID=58671740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018071087-3A BR112018071087A2 (pt) | 2016-04-13 | 2017-04-13 | composições e métodos de vacinação contra o vírus da dengue em crianças e adultos jovens |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11007261B2 (https=) |
| EP (1) | EP3442571A1 (https=) |
| JP (3) | JP2019511533A (https=) |
| KR (1) | KR102611235B1 (https=) |
| CN (2) | CN109069615B (https=) |
| AU (2) | AU2017250696A1 (https=) |
| BR (1) | BR112018071087A2 (https=) |
| CA (1) | CA3020484A1 (https=) |
| CO (1) | CO2018011355A2 (https=) |
| MX (1) | MX2018012459A (https=) |
| MY (1) | MY192806A (https=) |
| PH (1) | PH12018502175B1 (https=) |
| SG (2) | SG11201808906RA (https=) |
| WO (1) | WO2017179017A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20231581T1 (hr) | 2013-03-15 | 2024-03-15 | Takeda Vaccines, Inc. | Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima |
| US11007261B2 (en) * | 2016-04-13 | 2021-05-18 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
| TWI766876B (zh) * | 2016-08-03 | 2022-06-11 | 美商武田疫苗股份有限公司 | 用於與經改良之調配物一起穩定黃病毒的組成物及方法 |
| WO2019112921A1 (en) * | 2017-12-07 | 2019-06-13 | Merck Sharp & Dohme Corp. | Formulations of dengue virus vaccine compositions |
| WO2020051334A1 (en) * | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
| US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| MX2022001742A (es) * | 2019-08-16 | 2022-04-07 | Takeda Vaccines Inc | Metodos para prevenir el dengue y la hepatitis a. |
| EP4110381A1 (en) | 2020-02-27 | 2023-01-04 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| EP3892737A1 (en) * | 2020-04-09 | 2021-10-13 | Takeda Vaccines, Inc. | Qualitative and quantitative determination of single virus haplotypes in complex samples |
| WO2023147337A2 (en) | 2022-01-25 | 2023-08-03 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2023158989A1 (en) | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
| EP4519847A1 (en) | 2022-05-04 | 2025-03-12 | Takeda Vaccines, Inc. | Computer-based determination of flavivirus infectivity |
| EP4357464A1 (en) * | 2022-10-20 | 2024-04-24 | Takeda Vaccines, Inc. | A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype |
| WO2024097725A1 (en) * | 2022-11-02 | 2024-05-10 | Takeda Vaccines, Inc. | A method for determining the infectivity of a virus |
| EP4375381B1 (en) | 2022-11-18 | 2026-02-25 | Takeda Vaccines, Inc. | A method for determining the proportion of a live, attenuated dengue virus having a nucleotide sequence comprising at least one attenuation locus in a formulation |
| CN120529951A (zh) | 2022-11-29 | 2025-08-22 | 武田疫苗股份有限公司 | 大规模黄病毒疫苗生产和制造 |
| WO2025122855A1 (en) | 2023-12-08 | 2025-06-12 | Takeda Vaccines, Inc. | A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE481982T1 (de) * | 2002-05-03 | 2010-10-15 | Us Gov Health & Human Serv | Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2. |
| NZ597000A (en) | 2009-06-01 | 2014-07-25 | Takeda Vaccines Inc | Compositions and methods for administration of vaccines against dengue virus |
| US8968996B2 (en) * | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| EP2771366A4 (en) * | 2011-10-25 | 2015-06-03 | Florida Gulf Coast University Board Of Trustees | VACCINES AND METHOD FOR PRODUCING A VACCINE FOR INDUCING IMMUNITY AGAINST ALL SERGENT TYPES OF THE DENGUE VIRUS |
| NZ630831A (en) * | 2012-06-10 | 2019-02-22 | Takeda Vaccines Inc | Compositions and methods for administration of vaccines against dengue virus |
| MX381497B (es) * | 2012-07-24 | 2025-03-12 | Sanofi Pasteur | Composiciones vacuna. |
| TW201920677A (zh) * | 2012-11-08 | 2019-06-01 | 美商武田疫苗股份有限公司 | 登革熱病毒血清型４型之建構物的組成物、方法及用途 |
| JP2016504315A (ja) | 2012-12-14 | 2016-02-12 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 三価デングウイルス製剤に関する組成物、投与方法および使用 |
| HRP20231581T1 (hr) * | 2013-03-15 | 2024-03-15 | Takeda Vaccines, Inc. | Pripravci i postupci za kimerne konstrukte virusa denga groznice u cjepivima |
| TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
| US11007261B2 (en) * | 2016-04-13 | 2021-05-18 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
| WO2020051334A1 (en) * | 2018-09-05 | 2020-03-12 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| US11464815B2 (en) * | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
-
2017
- 2017-04-13 US US16/093,385 patent/US11007261B2/en active Active
- 2017-04-13 MY MYPI2018001735A patent/MY192806A/en unknown
- 2017-04-13 CN CN201780028507.XA patent/CN109069615B/zh active Active
- 2017-04-13 WO PCT/IB2017/052160 patent/WO2017179017A1/en not_active Ceased
- 2017-04-13 MX MX2018012459A patent/MX2018012459A/es unknown
- 2017-04-13 SG SG11201808906RA patent/SG11201808906RA/en unknown
- 2017-04-13 SG SG10201913383RA patent/SG10201913383RA/en unknown
- 2017-04-13 AU AU2017250696A patent/AU2017250696A1/en not_active Abandoned
- 2017-04-13 PH PH1/2018/502175A patent/PH12018502175B1/en unknown
- 2017-04-13 CN CN202510170711.1A patent/CN120392993A/zh active Pending
- 2017-04-13 CA CA3020484A patent/CA3020484A1/en active Pending
- 2017-04-13 EP EP17721858.3A patent/EP3442571A1/en active Pending
- 2017-04-13 JP JP2018553428A patent/JP2019511533A/ja active Pending
- 2017-04-13 KR KR1020187032733A patent/KR102611235B1/ko active Active
- 2017-04-13 BR BR112018071087-3A patent/BR112018071087A2/pt active Search and Examination
-
2018
- 2018-10-24 CO CONC2018/0011355A patent/CO2018011355A2/es unknown
- 2018-11-19 AU AU2018267542A patent/AU2018267542B2/en active Active
-
2021
- 2021-04-13 US US17/229,109 patent/US20210236620A1/en not_active Abandoned
-
2022
- 2022-04-20 JP JP2022069423A patent/JP2022089964A/ja active Pending
-
2024
- 2024-03-21 JP JP2024044760A patent/JP2024071463A/ja not_active Withdrawn
- 2024-08-30 US US18/821,030 patent/US20250235522A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11007261B2 (en) | 2021-05-18 |
| MX2018012459A (es) | 2019-06-06 |
| SG10201913383RA (en) | 2020-03-30 |
| CN109069615B (zh) | 2025-03-04 |
| AU2018267542B2 (en) | 2020-06-18 |
| KR102611235B1 (ko) | 2023-12-08 |
| KR20180137514A (ko) | 2018-12-27 |
| AU2018267542A1 (en) | 2018-12-13 |
| JP2022089964A (ja) | 2022-06-16 |
| PH12018502175B1 (en) | 2023-12-06 |
| WO2017179017A1 (en) | 2017-10-19 |
| AU2017250696A1 (en) | 2018-11-22 |
| SG11201808906RA (en) | 2018-11-29 |
| CN109069615A (zh) | 2018-12-21 |
| PH12018502175A1 (en) | 2019-10-28 |
| US20250235522A1 (en) | 2025-07-24 |
| CN120392993A (zh) | 2025-08-01 |
| EP3442571A1 (en) | 2019-02-20 |
| CO2018011355A2 (es) | 2018-11-13 |
| JP2024071463A (ja) | 2024-05-24 |
| MY192806A (en) | 2022-09-09 |
| US20190381163A1 (en) | 2019-12-19 |
| JP2019511533A (ja) | 2019-04-25 |
| US20210236620A1 (en) | 2021-08-05 |
| CA3020484A1 (en) | 2017-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018071087A2 (pt) | composições e métodos de vacinação contra o vírus da dengue em crianças e adultos jovens | |
| AR093421A1 (es) | Composiciones, metodos y usos de construcciones de virus del dengue de serotipo-4 | |
| ECSP23013715A (es) | Composiciones y métodos de construcciones quiméricas del virus del dengue en vacunas | |
| Appaiahgari et al. | IMOJEV®: a Yellow fever virus-based novel Japanese encephalitis vaccine | |
| JP2019511533A5 (https=) | ||
| JP2016513970A5 (https=) | ||
| BR112018077540A2 (pt) | vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado | |
| BR112018068342A2 (pt) | vacina de vírus zika vivo atenuado | |
| DE60041250D1 (de) | Multivalenter dengue-virus impfstoff | |
| JP2016504315A5 (https=) | ||
| JP2019511221A5 (https=) | ||
| CO2021017772A2 (es) | Virus del dengue atenuados | |
| BRPI0616224B1 (pt) | composição farmacêutica | |
| BR112021007105A2 (pt) | Zika vírus recombinante vivo atenuado, zika vírus recombinante, partícula de zika vírus recombinante ou ácido nucleico de zika vírus recombinante, ácido nucleico recombinante, isolado ou substancialmente purificado, vetor, célula ou isolado, vacina, preparação farmacêutica, composição imunogênica, uso, e, métodos para tratar um sujeito com uma infecção viral por zika natural, reduzir a gravidade de uma infecção viral por zika natural em um sujeito ou prevenir um sujeito de contrair uma infecção viral por zika naturalmente, para gerar uma vacina de zika vírus vivo atenuado, zika vírus recombinante, partícula de zika vírus recombinante ou ácido nucleico de zika vírus recombinante e para preparar uma vacina compreendendo zika vírus recombinante vivo atenuado | |
| BR112016029201A2 (pt) | vírus do oeste do nilo/dengue quiméricos e métodos de uso | |
| Wei et al. | Recent progress in dengue vaccine development | |
| BR0010969A (pt) | Vacina polivalente antivìrus da dengue | |
| TH170668A (th) | องค์ประกอบ และวิธีการสำหรับชุดโครงสร้างไคมีริกไวรัสเด็งกีในวัคซีน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122025028734-2 PROTOCOLO 870250118425 EM 22/12/2025 15:45.O PEDIDO FOI DIVIDIDO NO BR122025028734-2 PROTOCOLO 870250118425 EM 22/12/2025 15:45. |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] |